How Oncology Practices Lose Revenue and How to Stop It

Oncology is one of the most financially complex specialties in medicine. Between high-cost infusion drugs, prior authorizations, multi-payer coordination, and constantly shifting coding requirements, even well-run practices leak revenue without realizing it. A 2025 MGMA report found that oncology practices experience some of the highest claim denial rates of any specialty often north of 10%, compared to a 5–8% industry average. That gap isn’t random. It’s structural, and in most cases, it’s fixable.

This article breaks down exactly where oncology practices lose money, why it happens at each stage of the billing cycle, and what a stronger, more deliberate approach to revenue cycle management actually looks like in practice not in theory.

Why Oncology Billing Is Uniquely High-Risk

Most specialties bill for a visit, a procedure, or a defined course of treatment. Oncology bills for all three simultaneously often within the same encounter while also managing a set of variables most other specialties never have to touch:

• High-dollar drug claims (chemotherapy, immunotherapy, biologics) that require precise HCPCS coding and exact units billing
• Frequent prior authorizations that must be renewed every time a treatment plan changes
• Multiple concurrent payers for patients receiving coordinated care across oncology, radiology, and surgery
• Site-of-care billing differences between hospital-based infusion centers and freestanding clinics
• Rapid coding updates tied to newly approved drugs, biosimilars, and evolving treatment protocols
• Documentation burden tied to medical necessity for expensive, high-scrutiny therapies

Each of these is a point where a claim can be delayed, underpaid, or denied outright. Because oncology claims tend to carry high dollar values compared to most specialties, even a modest error rate translates into a disproportionately large revenue impact which is exactly why denial rates that look “acceptable” on paper can still represent six figures in lost or delayed revenue for a mid-sized practice.

Where the Revenue Actually Leaks

1. Drug and Infusion Coding Errors

Chemotherapy and infusion billing require exact matching between HCPCS codes, National Drug Codes (NDCs), administered units, and documented wastage. A single mismatched unit calculation billing 200mg instead of the 180mg actually administered, for example, can trigger an automatic denial or, worse, flag the claim for a payer audit months later. These errors are rarely intentional; they’re usually the result of billers working from general medical coding knowledge rather than oncology-specific training.

2. Prior Authorization Gaps

Oncology treatment plans shift constantly based on patient response, tolerance, and disease progression. If a prior authorization isn’t updated the moment a regimen changes a dosage adjustment, a switch in drug, an added supportive therapy that claim for that visit is denied, even though the care delivered was medically necessary and fully documented. Because authorizations are tied to specific drugs, dosages, and timeframes, this is one of the most common and most preventable sources of denial in oncology billing.

3. Denial Management That Reacts Instead of Prevents

Many practices only work denials after they’ve already happened, which means revenue sits delayed for 30, 60, sometimes 90-plus days while staff draft and submit appeals. Practices with strong oncology revenue cycle management build denial prevention into the front end of the process verifying eligibility, confirming authorization status, and checking coding accuracy before the claim is ever submitted, rather than fixing it after the fact.

4. Understaffed or Generalist Billing Teams

General medical billers often aren’t trained on oncology-specific coding nuances NDC-to-HCPCS crosswalks, drug wastage documentation rules, or infusion time-based billing increments. Without dedicated oncology expertise on the team, error rates climb steadily, and so does the practice’s average days in A/R. This is often the root cause behind a practice that “does everything right” clinically but still struggles financially.

5. Slow Follow-Up on Aging Claims

Every day a claim sits unworked past 30 days in A/R, the odds of full recovery decrease. Payers deprioritize older claims, appeal windows begin closing, and staff attention shifts to newer, easier-to-resolve issues. Practices without dedicated oncology billing management processes often don’t have the staff bandwidth to work aging claims aggressively and that lost time compounds directly into lost revenue.

6. Underpayment That Goes Unnoticed

Not every revenue leak comes from an outright denial. Underpayments where a payer reimburses less than the contracted rate are common in oncology because of the sheer volume and complexity of line items per claim. Without systematic contract-rate reconciliation, these underpayments often go completely unnoticed and unrecovered.

What Strong Oncology Revenue Cycle Management Actually Looks Like

The fix isn’t a single tactic it’s a system. Practices that successfully stop the leak typically have four things in place, working together rather than in isolation:

1. Front-end accuracy — eligibility, authorization, and coding checks completed before submission, not corrected after denial
2. Specialized coding expertise — billers trained specifically in oncology drug and infusion coding, not general E/M billing
3. Proactive denial management — a defined, fast-turnaround process for the small percentage of claims that are still denied despite front-end checks
4. Transparent reporting — ongoing visibility into clean claim rate, days in A/R, and collection ratio, so problems are caught in week two, not month three

This is the operating model behind AffinityCore’s oncology billing services built specifically around the coding complexity and reimbursement patterns unique to oncology, rather than adapted from a general medical billing playbook.

How AffinityCore Helps Oncology Practices Close the Gap

AffinityCore‘s oncology billing services are built around the specific failure points outlined above not retrofitted from a general medical billing model. Our coding team works exclusively with oncology-specific HCPCS, NDC, and infusion billing rules, so drug and units errors are caught before a claim goes out, not after it’s denied. Prior authorizations are tracked and renewed proactively as treatment plans change, closing one of the most common and most preventable denial gaps in oncology billing.

On the back end, our oncology revenue cycle management process includes systematic denial prevention, aging A/R follow-up, and contract-rate reconciliation to catch underpayments that often go unnoticed. Practices get transparent, ongoing reporting on clean claim rate, days in A/R, and collections so issues surface in weeks, not quarters. The result is a billing operation that behaves like an extension of your practice, not a black box you have to chase for answers.

The Cost of Waiting

Every month a practice continues operating with a reactive billing process, the gap compounds. Denied claims age past the point of easy appeal. Billing staff spend their time chasing old claims instead of preventing new denials from happening in the first place. And practice leadership ends up making financial and staffing decisions based on incomplete or delayed revenue data which makes it harder to catch the next leak before it happens.

Practices that shift to a specialized, prevention-first billing approach typically see measurable improvement within one to two billing cycles: cleaner claims on first submission, faster average reimbursement timelines, and far fewer surprises during month-end reporting.

Frequently Asked Questions

Why do oncology practices have higher claim denial rates than other specialties?

Oncology billing involves complex drug and infusion coding, frequent prior authorization changes, and multi-payer coordination all of which create more opportunities for errors than standard visit-based billing common in other specialties.

What is the biggest cause of denied oncology claims?

Coding errors related to chemotherapy and infusion drugs particularly mismatched units, NDC-to-HCPCS crosswalk errors, and missing wastage documentation are among the most common causes of oncology claim denials.

How can an oncology practice reduce claim denials?

Practices reduce denials by verifying eligibility and prior authorization before the visit, using oncology-trained coders, and correcting errors at the front end of the billing process rather than after a denial has already occurred.

How much revenue do oncology practices typically lose to billing errors?

It varies by practice size and payer mix, but denial rates above the specialty average of 10% can represent hundreds of thousands of dollars annually in delayed or lost reimbursement for a mid-sized oncology group.

Should oncology practices outsource their billing?

Many practices outsource to specialized oncology billing services to gain access to trained coders, proactive denial management, and reporting infrastructure that would be costly and time-consuming to build in-house.